BULGARIA - SUCCESS FOR NIHFI LTD

Bulgaria's Chemical Pharmaceutical Research Institute (NIHFI) Ltd has achieved good results in its pharmaceutical research, development and manufacturing activities, according to the Bulgarian Economic Review.

The company has seven R&D departments, four pharmaceutical pilot plants and a computer database of research information. Although much of its work is concerned with the research side of the industry, it also manufactures generic medicines for the domestic and international markets. Included in its production schedule are the anticancer agent tamoxifen (5mg tablets), trimezol, ketotifen, glibenclamide, idumed, bromocriptine, naproxen and verapamil.

Around 80% of the technologies used by Bulgarian pharmaceutical companies for the manufacture of raw materials and medicines are developed by NIHFI Ltd, the Review notes.